Nearly all patients with metastatic prostate cancer will develop hormone-refractory disease that results in progressive clinical deterioration and ultimately death. Still today the choice of the best treatment for this neoplasm represents a challenge for geriatric oncologists. In this scenario a comprehensive geriatric assessment plays a key role. In fact, patients with a good performance status and without comorbidities may be suitable for a docetaxel-based and vinorelbine-based first and second line chemotherapy, respectively. On the contrary subjects with a poor performance status and with an ADL or IADL dependance can receive only a palliative treatment with the aim of preserve their quality of life.
|Translated title of the contribution||Which therapy for elderly patients with hormone-refractory prostatic carcinoma?|
|Number of pages||11|
|Journal||Geriatric and Medical Intelligence|
|Publication status||Published - Jul 2005|
ASJC Scopus subject areas
- Geriatrics and Gerontology